arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

NEOGENOMICS INC

NEO
$18.36 ▼ -0.53 (-2.81%) at close
Industrials ·Services-Testing Laboratories ·USServices-Testing Laboratories
65 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

NEOGENOMICS INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.4B
Dividend Yield —
Revenue Growth 11.2% →
Op. Margin -4.8% ↗
ROIC -1.0% ↗
FCF / Share $0.09 ↗
Trailing P/E —
Price / Book 3.0x
FCF Yield 0.5%
Debt / Equity 0.48
info Valuation on last close. End-of-day price, Sep 23, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$201.66M
↑ +11.2% —
Net Income Profit after all expenses
$-17.11M
↑ +34.0% —
Operating Margin Operating profit as % of sales
-4.8%
↑ +50.4% 12th
FCF / Share Free cash flow per share
$0.09
↑ +189.0% —
Long-Term Debt Long-term obligations
$374.24M
↑ +9.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
15
Returns ↓
32
Financial Health →
36
Cash Quality ↓
29

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 65 quarters